← 返回专利悬崖列表
CAS 32384-65-9
(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one
登记编号：EMPA-007、DAPA-005、CANA-006、IPRA-012、ERTU-013、HENAG-007
应用背景（按来源药适应症）
慢性肾功能不全恩格列净心脏衰竭恩格列净二型糖尿病恩格列净二型糖尿病达格列净丙二醇/盐酸二甲双胍终末期肾脏病卡格列净/盐酸二甲双胍心脏和血管疾病卡格列净/盐酸二甲双胍腹主动脉瘤卡格列净/盐酸二甲双胍二型糖尿病卡格列净/盐酸二甲双胍二型糖尿病磷酸西格列汀一水合物/伊格列净L-脯氨酸盐二型糖尿病艾托格列净二尖瓣闭锁不全艾托格列净左心室功能不全艾托格列净心脏衰竭艾托格列净动脉粥样硬化艾托格列净胰岛素抵抗艾托格列净慢性肾功能不全达格列净丙二醇一水化物心脏衰竭达格列净丙二醇一水化物肾脏疾病达格列净丙二醇一水化物一型糖尿病达格列净丙二醇一水化物二型糖尿病达格列净丙二醇一水化物多囊卵巢综合征达格列净丙二醇一水化物二型糖尿病卡格列净糖尿病肾病卡格列净冠状动脉病变卡格列净糖尿病卡格列净心脏衰竭卡格列净终末期肾脏病卡格列净二型糖尿病伊格列净L-脯氨酸盐一型糖尿病伊格列净L-脯氨酸盐糖尿病伊格列净L-脯氨酸盐肝脏疾病伊格列净L-脯氨酸盐二型糖尿病脯氨酸恒格列净舒张期心力衰竭脯氨酸恒格列净非酒精性脂肪性肝炎脯氨酸恒格列净肾脏疾病脯氨酸恒格列净糖尿病脯氨酸恒格列净肝功能衰退脯氨酸恒格列净
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 恩格列净Empagliflozin | Tier A · 立即攻坚 | 2028 |
| 达格列净丙二醇/盐酸二甲双胍Dapagliflozin Propanediol/Metformin Hydrochloride | Tier A · 立即攻坚 | 2030 |
| 卡格列净/盐酸二甲双胍Canagliflozin/Metformin Hydrochloride | Tier B · 提前布局 | 2029 |
| 磷酸西格列汀一水合物/伊格列净L-脯氨酸盐Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline | Tier C · 观察 / 贸易 | - |
| 艾托格列净Ertugliflozin | Tier C · 观察 / 贸易 | - |
| 达格列净丙二醇一水化物Dapagliflozin Propanediol Monohydrate | Tier B · 提前布局 | - |
| 卡格列净Canagliflozin Hemihydrate | Tier C · 观察 / 贸易 | - |
| 伊格列净L-脯氨酸盐Ipragliflozin L-Proline | Tier C · 观察 / 贸易 | - |
| 脯氨酸恒格列净Henagliflozin Proline | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
5-bromo-2-chlorobenzoic acid→anisole→(5-bromo-2-chlorophenyl)(4-methoxyphenyl)methanone→4-bromo-1-chloro-2-(4-methoxybenzyl)benzene→4-(5-bromo-2-chlorobenzyl)phenol→(4-(5-bromo-2-chlorobenzyl)phenoxy)(tert-butyl)dimethylsilane→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol→(R)-tetrahydrofuran-3-yl 4-methylbenzenesulfonate→(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one
(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→2-chloro-5-iodobenzoic acid→fluorobenzene→(2-chloro-5-iodophenyl)(4-fluorophenyl)methanone→(S)-tetrahydrofuran-3-ol→(S)-(2-chloro-5-iodophenyl)(4-((tetrahydrofuran-3-yl)oxy)phenyl)methanone→(S)-3-(4-(2-chloro-5-iodobenzyl)phenoxy)tetrahydrofuran→(2S,3R,4S,5R,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-ol→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(S)-3-(4-bromophenoxy)tetrahydrofuran→5-bromo-2-chlorobenzaldehyde→(5-bromo-2-chlorophenyl)(4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)methanol→((5-bromo-2-chlorophenyl)(4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)methoxy)trimethylsilane→(2S,3R,4S,5R,6R)-2-(4-chloro-3-((4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)((trimethylsilyl)oxy)methyl)phenyl)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-ol→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(methoxy(4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate→5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one
5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→L-proline compound with (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1)
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 | 操作 |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | 2,3,4,6-Tetrakis-0-trimethylsilyl-D-gluconolactone Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。